HYPOXIA-INDUCIBLE FACTOR AS A MOLECULAR TARGET IN HEPATORENAL SYNDROME

被引:0
|
作者
Virstyuk, N. G. [1 ]
Slyvka, N. A. [2 ]
机构
[1] Ivano Frankivsk Natl State Med Univ, Int Ukrainian Univ, Ivano Frankivsk, Ukraine
[2] Bukovinian State Med Univ, Inst Internal Affairs Ukraine, Chernovtsy, Ukraine
来源
WORLD OF MEDICINE AND BIOLOGY | 2018年 / 65卷 / 03期
关键词
hepatorenal syndrome (HRS); alcoholic liver cirrhosis (ALC); hypoxia-inducible factor; hepatic renal failure;
D O I
10.26724/2079-8334-2018-3-65-23-28
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Hepatorenal syndrome (HRS) is a serious complication of alcohol liver cirrhosis (ALC). Studying of the mechanisms of molecular response to hypoxia in HRS is a promising direction of research in hepatology. The aim of present study was to evaluate the role of hypoxia-inducible factor HIF-1 alpha in the pathogenesis of HRS at the acute-on-chronic (ACLF) liver failure (CLF) in patients with ALC. 150 patients with ALC+ HRS were divided into 2 groups: I group (n= 67) -CLF,II group(n= 83) - ACLF. Level of HIF-1 alpha in the most severe category of patients in group 2, with stage IV by CLIF-C-ACLF scale, was almost three times higher than that of a similar category in group 1, with Child-Pugh C class, and was 30 +/- 7,9 ng/ml. Dramatic increase of HIF-1a level in the group 2 patients with the IV stage by CLIF-C-ACLF scale confirms the severe tissue hypoxia, which is caused by a significant deterioration of the splanchnic blood flow and spasm of renal vessels at the HRS. HIF-1 alpha levels closely correlate with the indicators of hepatic and renal failure in the patients with ALC+HRS, which allows to use it as an indicator for comprehensive diagnosis of this disease.
引用
收藏
页码:23 / 28
页数:7
相关论文
共 50 条
  • [1] Hypoxia-inducible factor as a therapeutic target for cardioprotection
    Ong, Sang-Ging
    Hausenloy, Derek J.
    PHARMACOLOGY & THERAPEUTICS, 2012, 136 (01) : 69 - 81
  • [2] Hypoxia-inducible factor 2α: a novel target in gliomas
    Renfrow, Jaclyn J.
    Soike, Michael H.
    Debinski, Waldemar
    Ramkissoon, Shakti H.
    Mott, Ryan T.
    Frenkel, Mark B.
    Sarkaria, Jann N.
    Lesser, Glenn J.
    Strowd, Roy E.
    FUTURE MEDICINAL CHEMISTRY, 2018, 10 (18) : 2227 - 2236
  • [3] The insights into molecular pathways of hypoxia-inducible factor in the brain
    Ostrowski, Robert P.
    Zhang, John H.
    JOURNAL OF NEUROSCIENCE RESEARCH, 2020, 98 (01) : 57 - 76
  • [4] Molecular Responses to Hypoxia-Inducible Factor 1α and Beyond
    Brocato, Jason
    Chervona, Yana
    Costa, Max
    MOLECULAR PHARMACOLOGY, 2014, 85 (05) : 651 - 657
  • [5] Hypoxia-inducible factor-1 as a therapeutic target in cancer
    Tang, Ceen-Ming
    Yu, Jun
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2013, 28 (03) : 401 - 405
  • [6] The hypoxia-inducible factor HIF as a new target in cancer research
    L'Allemain, G
    BULLETIN DU CANCER, 2002, 89 (03) : 257 - 260
  • [7] Hypoxia-Inducible Factor: A Potential Therapeutic Target for Rheumatoid Arthritis
    Zhao, Xuli
    Yue, Ye
    Cheng, Wengxiang
    Li, Jingchao
    Hu, Yiping
    Qin, Ling
    Zhang, Peng
    CURRENT DRUG TARGETS, 2013, 14 (06) : 700 - 707
  • [8] Effects of curcumin on hypoxia-inducible factor as a new therapeutic target
    Bahrami, Afsane
    Atkin, Stephen L.
    Majeed, Muhammed
    Sahebkar, Amirhossein
    PHARMACOLOGICAL RESEARCH, 2018, 137 : 159 - 169
  • [9] Hypoxia-inducible factor 1 as a possible target for cancer chemoprevention
    Lopez-Lazaro, Miguel
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2006, 15 (12) : 2332 - 2335
  • [10] Hypoxia-inducible factor in brain
    Sharp, FR
    Bergeron, M
    Bernaudin, M
    HYPOXIA: FROM GENES TO THE BEDSIDE, 2001, 502 : 273 - 291